@article{e8d1544130e84cce9699aa629fac1ad1,
title = "In Reply to Struikmans et al.",
author = "Mutter, {Robert W.} and Choi, {J. Isabelle} and Jimenez, {Rachel B.} and Kirova, {Youlia M.} and Marcio Fagundes and Haffty, {Bruce G.} and Amos, {Richard A.} and Bradley, {Julie A.} and Chen, {Peter Y.} and Xuanfeng Ding and Carr, {Antoinette M.} and Taylor, {Leslie M.} and Mark Pankuch and Vega, {Raymond B.Mailhot} and Ho, {Alice Y.} and Nystr{\"o}m, {Petra Witt} and McGee, {Lisa A.} and Urbanic, {James J.} and Oren Cahlon and Maduro, {John H.} and MacDonald, {Shannon M.}",
note = "Funding Information: Disclosures: R.B.M.V. reports travel funds from Varian (2017) and IBA (2018). J.A.B. reports travel funds from IBA (2018). Unrelated to this manuscript, A.Y.H. has received research funding from Merck and GSK and received consulting fees from La Roche Posay. M.F. reports being a consultant for Augmenix and Boston Scientific related to lecturing and training of new users of rectal spacers. Unrelated to this manuscript, R.A.A. reports being on the scientific advisory board and receiving honoraria from TAE Life Sciences. X.D. has a patent related to spot-scanning proton arc therapy and this patent has been licensed to IBA. ",
year = "2022",
month = apr,
day = "1",
doi = "10.1016/j.ijrobp.2021.12.155",
language = "English (US)",
volume = "112",
pages = "1289--1290",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",
}